Currently there have been three generation of EGFR Tyrosine-Kinase Inhibitors (TKIs) approved for the treatment of patients with EGFR-mutant NSCLC: the first-generation reversible EGFR TKIs including gefitinib and erlotinib, the second-generation irreversible EGFR TKIs such as dacomitinib and afatinib, and the recently approved third-generation EGFR TKI, Osimertinib.10, 11, 12 EGFR TKIs can bind to the ATP-binding site of the intracellular tyrosine kinase and suppress the autophosphorylation of EGFR, thus inhibiting the EGFR signaling and tumor progression. Here, EGFR is linked to non-small cell lung carcinoma.